▎ WuXi AppTec content team editor

Recently, Relay Therapeutics announced positive interim data

Cholangiocarcinoma is a rare malignancy that can be divided into intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma

RLY-4008 is the development of a specific inhibitor

Patients enrolled in the ReFocus trial have advanced solid tumors whose FGFR2 gene fusion/rearrangement is confirmed

Image credit: 123RF

As of 1 August this year, efficacy data were included in 38 patients with cholangiocarcinoma who had been previously treated with FGFR2 fusion/rearrangement and had not previously received FGFR inhibitors

Among patients receiving all doses (N=195), the most common treatment-related adverse effects (TRAE) were low-grade stomatitis (48%), acromegaly (46%), and dry mouth (31%)

According to the published summary, RLY-4008 is a promising next-generation inhibitor that could revolutionize the treatment of patients with bile duct cancer who have not previously received FGFR inhibitor therapy

WuXi AppTec provides integrated, end-to-end new drug development and production services to the global biopharmaceutical industry, covering chemical drug development and production, biological research, preclinical and clinical trial development, cell and gene therapy research and development, testing and production
.

If you have relevant business needs, please click on the image below to fill in the specific information
.

▲If you have any business needs, please long press to scan the QR code above, or